Lilly lifts 2026 outlook on GLP-1 momentum and pipeline expansion
Lilly reported Q2 2026 revenue of $23.0B, up 48% from a year earlier driven by Mounjaro and Zepbound, with GAAP EPS of $7.94 and non-GAAP EPS of $8.38; the company raised its full-year guidance to $85-87B in revenue and $35.50-$36.50 in non-GAAP EPS (midpoint up about $2.78) offset by $3.03 of acquired IPR&D charges, and highlighted regulatory wins (EBGLYSS for atopic dermatitis, Jaypirca in the EU for CLL) and continued obesity pipeline progress (retatrutide) with a planned BLA in 1Q 2027; Lilly also completed multiple acquisitions and announced additional investments to expand manufacturing in Indiana, underscoring a broad, growing pipeline.